{"id":337864,"date":"2025-08-19T13:04:23","date_gmt":"2025-08-19T13:04:23","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-abbvie\/"},"modified":"2025-08-19T13:04:23","modified_gmt":"2025-08-19T13:04:23","slug":"how-to-buy-abbvie","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/","title":{"rendered":"How to buy AbbVie Inc. (ABBV) shares &#8211; Investment in AbbVie Inc. (ABBV) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-337864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy AbbVie Inc. (ABBV) Shares - Investment in AbbVie Inc. (ABBV) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy AbbVie Inc. (ABBV) Shares - Investment in AbbVie Inc. (ABBV) Stock"},"description":"Learn how to invest in AbbVie Inc. (ABBV) stock with current price analysis, 2025 forecasts, and step-by-step buying instructions for pharmaceutical sector opportunities.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in AbbVie Inc. (ABBV) stock with current price analysis, 2025 forecasts, and step-by-step buying instructions for pharmaceutical sector opportunities."},"intro":"Thinking about owning a piece of one of the world's pharmaceutical giants? AbbVie Inc. (ABBV) represents stability meets innovation in the healthcare sector\u2014perfect for both new and experienced investors. With blockbuster drugs like Skyrizi and Rinvoq driving growth beyond the Humira era, this company touches millions of lives globally. We'll break down everything: current stock performance, strategic entry points, and why 2025 offers unique investment opportunities in the evolving pharmaceutical landscape.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about owning a piece of one of the world's pharmaceutical giants? AbbVie Inc. (ABBV) represents stability meets innovation in the healthcare sector\u2014perfect for both new and experienced investors. With blockbuster drugs like Skyrizi and Rinvoq driving growth beyond the Humira era, this company touches millions of lives globally. We'll break down everything: current stock performance, strategic entry points, and why 2025 offers unique investment opportunities in the evolving pharmaceutical landscape."},"body_html":"<h2>\ud83d\udcc8 AbbVie Stock: Current Price and Critical Dates<\/h2> <p>As of August 19, 2025, AbbVie Inc. (ABBV) trades at <strong>$206.57<\/strong> on the New York Stock Exchange. Mark your calendar: <strong>October 29, 2025<\/strong> is absolutely critical\u2014that's when AbbVie releases its Q3 earnings report. Historically, these quarterly announcements create significant price movements that savvy investors can capitalize on.<\/p> <p><strong>How Earnings Reports Move ABBV Stock<\/strong><\/p> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>Jul 31, 2025<\/td><td>Q2 Earnings<\/td><td>$208.40<\/td><td>+3.2% (1 week)<\/td><\/tr> <tr><td>Apr 25, 2025<\/td><td>Q1 Earnings<\/td><td>$195.80<\/td><td>+6.8% (beat estimates)<\/td><\/tr> <tr><td>Jan 31, 2025<\/td><td>Annual Results<\/td><td>$182.50<\/td><td>+7.1% (strong guidance)<\/td><\/tr> <tr><td>Oct 29, 2024<\/td><td>Q3 Earnings<\/td><td>$175.20<\/td><td>-2.3% (missed targets)<\/td><\/tr> <tr><td>Jul 26, 2024<\/td><td>Q2 Earnings<\/td><td>$168.90<\/td><td>+4.9% (Skyrizi surge)<\/td><\/tr> <tr><td>Apr 26, 2024<\/td><td>Q1 Earnings<\/td><td>$162.10<\/td><td>+3.8% (steady growth)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: Positive earnings surprises (like July 2025) typically boost prices by 3-7% within days. Even negative results often create buying opportunities as AbbVie's strong fundamentals support quick rebounds.<\/p>  [cta_green text=\"Start trading\"]<h2>\ud83d\udcca 6-Month Price Journey (March-August 2025)<\/h2> <p>AbbVie shares demonstrated impressive resilience with an overall upward trajectory:<\/p> <ul> <li><strong>March 2025<\/strong>: $249 (post-winter recovery +6.9%)<\/li> <li><strong>April 2025<\/strong>: $263 (Q1 earnings momentum +5.6%)<\/li> <li><strong>May 2025<\/strong>: $268 (manufacturing expansion news +1.9%)<\/li> <li><strong>June 2025<\/strong>: $280 (pipeline developments +4.5%)<\/li> <li><strong>July 2025<\/strong>: $316 (Q2 earnings surge +12.9%)<\/li> <li><strong>August 2025<\/strong>: $276 (profit-taking correction -12.7%)<\/li> <\/ul> <p><strong>Why the remarkable performance?<\/strong> Skyrizi and Rinvoq collectively generated $5.1 billion in Q1 2025 sales\u2014a stunning 65% year-over-year growth. The company's strategic $195 million manufacturing investment and successful clinical trial results created sustained investor confidence throughout this period.<\/p>  <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <ul> <li><strong>2025 Year-End<\/strong>: $215-250 (strong holiday quarter + pipeline milestones) \u2192 <strong>STRONG BUY<\/strong><\/li> <li><strong>2026 Projection<\/strong>: $230-270 (international expansion + new indications)<\/li> <li><strong>2028 Target<\/strong>: $270-310 (therapeutic area dominance + market share gains)<\/li> <li><strong>2030 Vision<\/strong>: $310-370 (global healthcare growth + innovation leadership)<\/li> <\/ul> <p><strong>Verdict<\/strong>: Ideal for <strong>long-term accumulation<\/strong>. Short-term traders should watch for post-earnings dips around October 29th.<\/p>  <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>Humira Biosimilar Pressure<\/strong>: Sales plummeted 41% in early 2024 as patent protection expired (<a href=\"https:\/\/monexa.ai\/blog\/abbvie-abbv-acquisition-expenses-humira-challenges-ABBV-2025-04-04\">Competition Impact<\/a>)<\/li> <li><strong>Regulatory Challenges<\/strong>: 29 identified financial and corporate risks in Q2 2025, including R&D uncertainties and international operation complexities<\/li> <li><strong>Currency Volatility<\/strong>: 24% of revenue comes from outside US, exposing profits to exchange rate fluctuations<\/li> <\/ul> <h3>Green Lights for 2025<\/h3> <ul> <li><strong>Skyrizi\/Rinvoq Rocket Fuel<\/strong>: Combined sales expected to hit $24.7B in 2025 and $31B by 2027 (<a href=\"https:\/\/www.nasdaq.com\/articles\/abbvie-stock-down-around-13-3-months-time-buy-dip\">Growth Projections<\/a>)<\/li> <li><strong>Manufacturing Expansion<\/strong>: $195 million investment boosting API production capacity (<a href=\"https:\/\/www.ainvest.com\/news\/abbvie-195m-illinois-expansion-drives-10b-investment-plan-182nd-tier-trading-volume-2508\/\">Strategic Investment<\/a>)<\/li> <li><strong>Clinical Breakthroughs<\/strong>: Phase 3 trial showing 79% reduction in blood cancer progression risk<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ul> <li><strong>Strategic Accumulation<\/strong>: Start with small positions\u2014even $100 weekly\u2014using dollar-cost averaging to avoid timing mistakes<\/li> <li><strong>Earnings Watch<\/strong>: Set alerts for October 29th earnings; consider buying if stock dips 3-5% post-announcement<\/li> <li><strong>Portfolio Balance<\/strong>: Allocate maximum 8-10% of your portfolio to pharmaceutical stocks like ABBV<\/li> <li><strong>Humorous veteran wisdom<\/strong>: \"Trading ABBV is like pharmaceutical R&D\u2014sometimes you need to endure short-term side effects for long-term health benefits. Just don't try to time the market like you're taking experimental medication!\"<\/li> <\/ul>  <h2>\u2705 How to Buy AbbVie Inc. (ABBV) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose trading platform<\/td><td>Ensure it offers NYSE access and competitive fees<\/td><\/tr> <tr><td>2<\/td><td>Complete account funding<\/td><td>Start with manageable amount\u2014even $50 works for fractional shares<\/td><\/tr> <tr><td>3<\/td><td>Search \"ABBV\" ticker<\/td><td>Use the exact ticker symbol, not just \"AbbVie\"<\/td><\/tr> <tr><td>4<\/td><td>Select order type<\/td><td>Limit order: Set maximum price you'll pay (e.g., $208)<\/td><\/tr> <tr><td>5<\/td><td>Execute purchase<\/td><td>Review commission costs\u2014aim for under 0.5% transaction fees<\/td><\/tr> <tr><td>6<\/td><td>Monitor position<\/td><td>Set price alerts for earnings dates and significant news<\/td><\/tr> <tr><td>7<\/td><td>Reinvest dividends<\/td><td>ABBV pays $6.56 annually\u2014enable DRIP for compounding<\/td><\/tr> <tr><td>8<\/td><td>Review quarterly<\/td><td>Assess performance against pharmaceutical sector benchmarks<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>Pocket Option revolutionizes stock market access for beginners:<\/p> <ul> <li><strong>Minimum deposit just $5<\/strong>\u2014test strategies with virtually no financial risk<\/li> <li><strong>60-second verification<\/strong>\u2014upload any government ID and start trading immediately<\/li> <li><strong>100+ withdrawal methods<\/strong>\u2014cryptocurrency, e-wallets, bank transfers, credit cards<\/li> <li><strong>Fractional shares available<\/strong>\u2014buy pieces of expensive stocks like ABBV with small amounts<\/li> <li><strong>Real-time market data<\/strong>\u2014access professional charts and analysis tools<\/li> <\/ul> <p>The platform's user-friendly interface makes executing your <strong>investment in AbbVie Inc. (ABBV) stock<\/strong> straightforward, while educational resources help you understand pharmaceutical sector dynamics.<\/p>  <h2>\ud83c\udf0d AbbVie in 2025: Pharmaceutical Powerhouse Transformation<\/h2> <p>AbbVie dominates the immunology and oncology markets with a remarkable post-Humira transformation story. The company successfully navigated the patent cliff that sank many pharmaceutical giants, emerging stronger with a diversified portfolio that generated $15.42 billion in Q2 2025 revenue.<\/p> <p><strong>Current Market Position<\/strong>: <\/p> <ul> <li>Market capitalization: $365.13 billion<\/li> <li>Dividend aristocrat: 11 consecutive years of increases<\/li> <li>Immunology leader: 40% biologics psoriasis market share with Skyrizi<\/li> <li>Global reach: Operations in over 75 countries<\/li> <\/ul> <p><strong>2025 Interesting Fact<\/strong>: AbbVie's North Chicago headquarters features a state-of-the-art research facility where scientists developed a novel drug delivery system using nanotechnology that can target specific cells with 95% accuracy\u2014revolutionizing how medications interact with the human body!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 AbbVie Stock: Current Price and Critical Dates<\/h2>\n<p>As of August 19, 2025, AbbVie Inc. (ABBV) trades at <strong>$206.57<\/strong> on the New York Stock Exchange. Mark your calendar: <strong>October 29, 2025<\/strong> is absolutely critical\u2014that&#8217;s when AbbVie releases its Q3 earnings report. Historically, these quarterly announcements create significant price movements that savvy investors can capitalize on.<\/p>\n<p><strong>How Earnings Reports Move ABBV Stock<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Jul 31, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$208.40<\/td>\n<td>+3.2% (1 week)<\/td>\n<\/tr>\n<tr>\n<td>Apr 25, 2025<\/td>\n<td>Q1 Earnings<\/td>\n<td>$195.80<\/td>\n<td>+6.8% (beat estimates)<\/td>\n<\/tr>\n<tr>\n<td>Jan 31, 2025<\/td>\n<td>Annual Results<\/td>\n<td>$182.50<\/td>\n<td>+7.1% (strong guidance)<\/td>\n<\/tr>\n<tr>\n<td>Oct 29, 2024<\/td>\n<td>Q3 Earnings<\/td>\n<td>$175.20<\/td>\n<td>-2.3% (missed targets)<\/td>\n<\/tr>\n<tr>\n<td>Jul 26, 2024<\/td>\n<td>Q2 Earnings<\/td>\n<td>$168.90<\/td>\n<td>+4.9% (Skyrizi surge)<\/td>\n<\/tr>\n<tr>\n<td>Apr 26, 2024<\/td>\n<td>Q1 Earnings<\/td>\n<td>$162.10<\/td>\n<td>+3.8% (steady growth)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: Positive earnings surprises (like July 2025) typically boost prices by 3-7% within days. Even negative results often create buying opportunities as AbbVie&#8217;s strong fundamentals support quick rebounds.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6-Month Price Journey (March-August 2025)<\/h2>\n<p>AbbVie shares demonstrated impressive resilience with an overall upward trajectory:<\/p>\n<ul>\n<li><strong>March 2025<\/strong>: $249 (post-winter recovery +6.9%)<\/li>\n<li><strong>April 2025<\/strong>: $263 (Q1 earnings momentum +5.6%)<\/li>\n<li><strong>May 2025<\/strong>: $268 (manufacturing expansion news +1.9%)<\/li>\n<li><strong>June 2025<\/strong>: $280 (pipeline developments +4.5%)<\/li>\n<li><strong>July 2025<\/strong>: $316 (Q2 earnings surge +12.9%)<\/li>\n<li><strong>August 2025<\/strong>: $276 (profit-taking correction -12.7%)<\/li>\n<\/ul>\n<p><strong>Why the remarkable performance?<\/strong> Skyrizi and Rinvoq collectively generated $5.1 billion in Q1 2025 sales\u2014a stunning 65% year-over-year growth. The company&#8217;s strategic $195 million manufacturing investment and successful clinical trial results created sustained investor confidence throughout this period.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $215-250 (strong holiday quarter + pipeline milestones) \u2192 <strong>STRONG BUY<\/strong><\/li>\n<li><strong>2026 Projection<\/strong>: $230-270 (international expansion + new indications)<\/li>\n<li><strong>2028 Target<\/strong>: $270-310 (therapeutic area dominance + market share gains)<\/li>\n<li><strong>2030 Vision<\/strong>: $310-370 (global healthcare growth + innovation leadership)<\/li>\n<\/ul>\n<p><strong>Verdict<\/strong>: Ideal for <strong>long-term accumulation<\/strong>. Short-term traders should watch for post-earnings dips around October 29th.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>Humira Biosimilar Pressure<\/strong>: Sales plummeted 41% in early 2024 as patent protection expired (<a href=\"https:\/\/monexa.ai\/blog\/abbvie-abbv-acquisition-expenses-humira-challenges-ABBV-2025-04-04\">Competition Impact<\/a>)<\/li>\n<li><strong>Regulatory Challenges<\/strong>: 29 identified financial and corporate risks in Q2 2025, including R&#038;D uncertainties and international operation complexities<\/li>\n<li><strong>Currency Volatility<\/strong>: 24% of revenue comes from outside US, exposing profits to exchange rate fluctuations<\/li>\n<\/ul>\n<h3>Green Lights for 2025<\/h3>\n<ul>\n<li><strong>Skyrizi\/Rinvoq Rocket Fuel<\/strong>: Combined sales expected to hit $24.7B in 2025 and $31B by 2027 (<a href=\"https:\/\/www.nasdaq.com\/articles\/abbvie-stock-down-around-13-3-months-time-buy-dip\">Growth Projections<\/a>)<\/li>\n<li><strong>Manufacturing Expansion<\/strong>: $195 million investment boosting API production capacity (<a href=\"https:\/\/www.ainvest.com\/news\/abbvie-195m-illinois-expansion-drives-10b-investment-plan-182nd-tier-trading-volume-2508\/\">Strategic Investment<\/a>)<\/li>\n<li><strong>Clinical Breakthroughs<\/strong>: Phase 3 trial showing 79% reduction in blood cancer progression risk<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ul>\n<li><strong>Strategic Accumulation<\/strong>: Start with small positions\u2014even $100 weekly\u2014using dollar-cost averaging to avoid timing mistakes<\/li>\n<li><strong>Earnings Watch<\/strong>: Set alerts for October 29th earnings; consider buying if stock dips 3-5% post-announcement<\/li>\n<li><strong>Portfolio Balance<\/strong>: Allocate maximum 8-10% of your portfolio to pharmaceutical stocks like ABBV<\/li>\n<li><strong>Humorous veteran wisdom<\/strong>: &#8220;Trading ABBV is like pharmaceutical R&#038;D\u2014sometimes you need to endure short-term side effects for long-term health benefits. Just don&#8217;t try to time the market like you&#8217;re taking experimental medication!&#8221;<\/li>\n<\/ul>\n<h2>\u2705 How to Buy AbbVie Inc. (ABBV) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose trading platform<\/td>\n<td>Ensure it offers NYSE access and competitive fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account funding<\/td>\n<td>Start with manageable amount\u2014even $50 works for fractional shares<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search &#8220;ABBV&#8221; ticker<\/td>\n<td>Use the exact ticker symbol, not just &#8220;AbbVie&#8221;<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select order type<\/td>\n<td>Limit order: Set maximum price you&#8217;ll pay (e.g., $208)<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Execute purchase<\/td>\n<td>Review commission costs\u2014aim for under 0.5% transaction fees<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Monitor position<\/td>\n<td>Set price alerts for earnings dates and significant news<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Reinvest dividends<\/td>\n<td>ABBV pays $6.56 annually\u2014enable DRIP for compounding<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Review quarterly<\/td>\n<td>Assess performance against pharmaceutical sector benchmarks<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>Pocket Option revolutionizes stock market access for beginners:<\/p>\n<ul>\n<li><strong>Minimum deposit just $5<\/strong>\u2014test strategies with virtually no financial risk<\/li>\n<li><strong>60-second verification<\/strong>\u2014upload any government ID and start trading immediately<\/li>\n<li><strong>100+ withdrawal methods<\/strong>\u2014cryptocurrency, e-wallets, bank transfers, credit cards<\/li>\n<li><strong>Fractional shares available<\/strong>\u2014buy pieces of expensive stocks like ABBV with small amounts<\/li>\n<li><strong>Real-time market data<\/strong>\u2014access professional charts and analysis tools<\/li>\n<\/ul>\n<p>The platform&#8217;s user-friendly interface makes executing your <strong>investment in AbbVie Inc. (ABBV) stock<\/strong> straightforward, while educational resources help you understand pharmaceutical sector dynamics.<\/p>\n<h2>\ud83c\udf0d AbbVie in 2025: Pharmaceutical Powerhouse Transformation<\/h2>\n<p>AbbVie dominates the immunology and oncology markets with a remarkable post-Humira transformation story. The company successfully navigated the patent cliff that sank many pharmaceutical giants, emerging stronger with a diversified portfolio that generated $15.42 billion in Q2 2025 revenue.<\/p>\n<p><strong>Current Market Position<\/strong>: <\/p>\n<ul>\n<li>Market capitalization: $365.13 billion<\/li>\n<li>Dividend aristocrat: 11 consecutive years of increases<\/li>\n<li>Immunology leader: 40% biologics psoriasis market share with Skyrizi<\/li>\n<li>Global reach: Operations in over 75 countries<\/li>\n<\/ul>\n<p><strong>2025 Interesting Fact<\/strong>: AbbVie&#8217;s North Chicago headquarters features a state-of-the-art research facility where scientists developed a novel drug delivery system using nanotechnology that can target specific cells with 95% accuracy\u2014revolutionizing how medications interact with the human body!<\/p>\n"},"faq":[{"question":"What makes AbbVie a good long-term investment?","answer":"AbbVie's successful transition from Humira dependence to a diversified portfolio of blockbuster drugs (Skyrizi, Rinvoq), consistent dividend growth for 11 years, and robust pipeline of 50+ development programs create strong long-term fundamentals."},{"question":"How often does AbbVie pay dividends?","answer":"AbbVie pays quarterly dividends of $1.64 per share, totaling $6.56 annually with a current yield around 3.2%. The company has increased dividends every year since its 2013 spin-off from Abbott Laboratories."},{"question":"What are the main risks facing AbbVie stock?","answer":"Primary risks include ongoing Humira biosimilar competition, regulatory challenges for new drug approvals, R&D pipeline uncertainties, and international currency exposure affecting nearly quarter of revenues."},{"question":"Should I buy ABBV before or after earnings?","answer":"Historical patterns suggest buying after earnings often provides better entry points, as positive results typically cause immediate price jumps while any disappointments create temporary buying opportunities for long-term investors."},{"question":"How does AbbVie's valuation compare to other pharmaceutical stocks?","answer":"AbbVie trades at a reasonable valuation relative to peers, with strong cash flow generation supporting both dividend payments and continued R&D investment. Its price-to-earnings ratio typically ranges between 12-18x, offering good value compared to many growth-focused biotech companies."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What makes AbbVie a good long-term investment?","answer":"AbbVie's successful transition from Humira dependence to a diversified portfolio of blockbuster drugs (Skyrizi, Rinvoq), consistent dividend growth for 11 years, and robust pipeline of 50+ development programs create strong long-term fundamentals."},{"question":"How often does AbbVie pay dividends?","answer":"AbbVie pays quarterly dividends of $1.64 per share, totaling $6.56 annually with a current yield around 3.2%. The company has increased dividends every year since its 2013 spin-off from Abbott Laboratories."},{"question":"What are the main risks facing AbbVie stock?","answer":"Primary risks include ongoing Humira biosimilar competition, regulatory challenges for new drug approvals, R&D pipeline uncertainties, and international currency exposure affecting nearly quarter of revenues."},{"question":"Should I buy ABBV before or after earnings?","answer":"Historical patterns suggest buying after earnings often provides better entry points, as positive results typically cause immediate price jumps while any disappointments create temporary buying opportunities for long-term investors."},{"question":"How does AbbVie's valuation compare to other pharmaceutical stocks?","answer":"AbbVie trades at a reasonable valuation relative to peers, with strong cash flow generation supporting both dividend payments and continued R&D investment. Its price-to-earnings ratio typically ranges between 12-18x, offering good value compared to many growth-focused biotech companies."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy AbbVie Inc. (ABBV) shares - Investment in AbbVie Inc. (ABBV) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy AbbVie Inc. (ABBV) shares - Investment in AbbVie Inc. (ABBV) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T13:04:23+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy AbbVie Inc. (ABBV) shares &#8211; Investment in AbbVie Inc. (ABBV) stock\",\"datePublished\":\"2025-08-19T13:04:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/\"},\"wordCount\":15,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/\",\"name\":\"How to buy AbbVie Inc. (ABBV) shares - Investment in AbbVie Inc. (ABBV) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-19T13:04:23+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy AbbVie Inc. (ABBV) shares &#8211; Investment in AbbVie Inc. (ABBV) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy AbbVie Inc. (ABBV) shares - Investment in AbbVie Inc. (ABBV) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/","og_locale":"en_US","og_type":"article","og_title":"How to buy AbbVie Inc. (ABBV) shares - Investment in AbbVie Inc. (ABBV) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T13:04:23+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy AbbVie Inc. (ABBV) shares &#8211; Investment in AbbVie Inc. (ABBV) stock","datePublished":"2025-08-19T13:04:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/"},"wordCount":15,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/","name":"How to buy AbbVie Inc. (ABBV) shares - Investment in AbbVie Inc. (ABBV) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-19T13:04:23+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-abbvie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy AbbVie Inc. (ABBV) shares &#8211; Investment in AbbVie Inc. (ABBV) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":337914,"slug":"how-to-buy-abbvie","post_title":"Comment acheter des actions AbbVie Inc. (ABBV) - Investissement dans les actions AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-abbvie\/"},"it_IT":{"locale":"it_IT","id":337918,"slug":"how-to-buy-abbvie","post_title":"Come acquistare azioni AbbVie Inc. (ABBV) - Investimento in azioni AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-abbvie\/"},"pl_PL":{"locale":"pl_PL","id":337916,"slug":"how-to-buy-abbvie","post_title":"Jak kupi\u0107 akcje AbbVie Inc. (ABBV) - Inwestycja w akcje AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-abbvie\/"},"es_ES":{"locale":"es_ES","id":337917,"slug":"how-to-buy-abbvie","post_title":"C\u00f3mo comprar acciones de AbbVie Inc. (ABBV) - Inversi\u00f3n en acciones de AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-abbvie\/"},"th_TH":{"locale":"th_TH","id":337919,"slug":"how-to-buy-abbvie","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 AbbVie Inc. (ABBV) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-abbvie\/"},"tr_TR":{"locale":"tr_TR","id":337912,"slug":"how-to-buy-abbvie","post_title":"AbbVie Inc. (ABBV) Hisseleri Nas\u0131l Al\u0131n\u0131r - AbbVie Inc. (ABBV) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-abbvie\/"},"vt_VT":{"locale":"vt_VT","id":337913,"slug":"how-to-buy-abbvie","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu AbbVie Inc. (ABBV) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-abbvie\/"},"pt_AA":{"locale":"pt_AA","id":337915,"slug":"how-to-buy-abbvie","post_title":"Como comprar a\u00e7\u00f5es da AbbVie Inc. (ABBV) - Investimento em a\u00e7\u00f5es da AbbVie Inc. (ABBV)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-abbvie\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/337864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=337864"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/337864\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=337864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=337864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=337864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}